Competitor Analysis: c-MET/HGF Inhibitors

The Competitive Intelligence Report c-MET/HGF Inhibitors as of June 2011 provides a competitor analysis in the development pipeline of novel emerging inhibitors of c-MET receptor tyrosine kinase (RTK) and its ligand hepatocyte growth factor (HGF) or scatter factor (SF) for treatment of solid tumors. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report. The c-MET signalling pathway consists of the mesenchymal epithelial transition factor (c-MET) transmembrane tyrosine kinase receptor and its ligand hepatocyte growth factor (HGF) or scatter factor (SF). Binding of HGF/SF to c-MET activates downstream signalling pathways such as Rho, focal adhesion kinase (FAK) and PI3K. These pathways regulate cancer cell growth, survival angiogenesis, invasion and metastasis. Thus, prevention of c-MET dependent neoplastic processes may provide a means for managing invasive tumors of high metastatic potential. In fact, c-MET/HGF has evolved as an attractive target for the pharmaceutical industry. The report includes a compilation of currently active projects in research and development of c-Met/HGF Inhibitors. In addition, the report lists company-specific R&D pipelines of c-Met/HGF inhibitors in R&D. Competitor projects are listed in a tabular format providing Information on: Drug Codes, Target / Mechanism of Action, Class of Compound, Company, Product category, Indication, R&D Stage and additional comments with a hyperlink leading to the source of information.

Additional Information

About Competitor Analysis Series:

The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.